Home
Conditions
Diffuse Large B-cell Lymphoma

Clinical trial condition

Diffuse Large B-cell Lymphoma

Explore clinical trials studying Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

217 public trials 53 recruiting studies

Refine in advanced search Browse all conditions

Diffuse Large B-cell Lymphoma trial results

Not yet recruiting

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT07159906

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, Zhejiang, China

View Trial Details

Not yet recruiting

G-Pola-ZLP in Diffuse Large B-Cell Lymphoma

NCT06665217

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Not specified

View Trial Details

Not yet recruiting

Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

NCT07012980

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Not specified

View Trial Details

Not yet recruiting

A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL

NCT06921044

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Not specified

View Trial Details

Not yet recruiting

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

NCT06441097

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Not specified

View Trial Details

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

NCT05990985

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: The First Bethune Hospital of Jilin University Changchun, Jilin, China

View Trial Details

Not yet recruiting

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

NCT05280626

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Not specified

View Trial Details

Enrolling by invitation

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

NCT05690191

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Second Affiliated Hospital of Soochow University Suzhou, Jiangsu, China

View Trial Details

Active, not recruiting

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

NCT06929624

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Beijing Cancer Hospital Beijing, Beijing Municipality, China

Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

View Trial Details

Active, not recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976

Conditions: Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations: University of Arkansas for Medical Sciences /ID# 225703 Little Rock, Arkansas, United States

CBCC Global Research, Inc. /ID# 262037 Bakersfield, California, United States

Alta Bates Summit Medical Center for Research /ID# 229427 Berkeley, California, United States

Orange Coast Memorial Medical Center /ID# 229632 Fountain Valley, California, United States

View all 331 locations

View Trial Details

Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma trial results

Related conditions